Literature DB >> 16951159

Degradation of Tob1 mediated by SCFSkp2-dependent ubiquitination.

Yoshihiro Hiramatsu1, Kyoko Kitagawa, Toru Suzuki, Chiharu Uchida, Takayuki Hattori, Hirotoshi Kikuchi, Toshiaki Oda, Shigetsugu Hatakeyama, Keiichi I Nakayama, Tadashi Yamamoto, Hiroyuki Konno, Masatoshi Kitagawa.   

Abstract

Tob1, a member of the Tob/BTG family, is involved in the control of G(1)-S progression by suppressing cyclin D1 expression and acts as a tumor suppressor gene. Tob1 was reported to have a quick turnover through the ubiquitin-proteasome pathway, but proteins involved in this process are still unknown. We showed that Skp2, a substrate-targeting subunit of the SCF (Skp1/Cul1/F-box protein) ubiquitin ligase complex, was involved in ubiquitin-dependent degradation of Tob1. Skp2 interacted with Tob1 and facilitated ubiquitination of Tob1 in intact cells as well as in vitro. Skp2 mutants without the F-box or leucine rich repeat were not able to bind to Tob1 and did not enhance ubiquitination of Tob1. Tob1 was stabilized in both Skp2(-/-) mouse fibroblasts and Skp2 knockdown HeLa cells. Moreover, cyclin D1 expression was suppressed in Skp2 knockdown HeLa cells. These data suggest that Tob1 is a novel target for degradation by the SCF-Skp2 ubiquitin ligase.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16951159     DOI: 10.1158/0008-5472.CAN-06-1603

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  25 in total

1.  S-phase kinase-associated protein 2 promotes cell growth and motility in osteosarcoma cells.

Authors:  Lu Ding; Rong Li; Rongxin Sun; Yang Zhou; Yubo Zhou; Xiaoping Han; Yong Cui; Wu Wang; Qing Lv; Jingping Bai
Journal:  Cell Cycle       Date:  2017-08-03       Impact factor: 4.534

Review 2.  Negative regulators in homeostasis of naïve peripheral T cells.

Authors:  Jaime F Modiano; Lisa D S Johnson; Donald Bellgrau
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

3.  Flipping the switch from g1 to s phase with e3 ubiquitin ligases.

Authors:  Lindsay F Rizzardi; Jeanette Gowen Cook
Journal:  Genes Cancer       Date:  2012-11

4.  The Putative Association of TOB1-AS1 Long Non-coding RNA with Immune Tolerance: A Study on Multiple Sclerosis Patients.

Authors:  Reyhaneh Dehghanzad; Majid Pahlevan Kakhki; Asieh Alikhah; Mohammad Ali Sahraian; Mehrdad Behmanesh
Journal:  Neuromolecular Med       Date:  2019-09-03       Impact factor: 3.843

Review 5.  Deregulation of F-box proteins and its consequence on cancer development, progression and metastasis.

Authors:  Jinho Heo; Rebeka Eki; Tarek Abbas
Journal:  Semin Cancer Biol       Date:  2015-09-30       Impact factor: 15.707

Review 6.  A patent review of the ubiquitin ligase system: 2015-2018.

Authors:  Xin Li; Ekinci Elmira; Sagar Rohondia; Jicang Wang; Jinbao Liu; Q Ping Dou
Journal:  Expert Opin Ther Pat       Date:  2018-11-23       Impact factor: 6.674

Review 7.  Recent advances in SCF ubiquitin ligase complex: Clinical implications.

Authors:  Nana Zheng; Quansheng Zhou; Zhiwei Wang; Wenyi Wei
Journal:  Biochim Biophys Acta       Date:  2016-05-05

8.  High-throughput screening AlphaScreen assay for identification of small-molecule inhibitors of ubiquitin E3 ligase SCFSkp2-Cks1.

Authors:  Dana Ungermannova; Junglim Lee; Gan Zhang; H Garry Dallmann; Charles S McHenry; Xuedong Liu
Journal:  J Biomol Screen       Date:  2013-04-15

9.  Cyclin G2 is degraded through the ubiquitin-proteasome pathway and mediates the antiproliferative effect of activin receptor-like kinase 7.

Authors:  Guoxiong Xu; Stefanie Bernaudo; Guodong Fu; Daniel Y Lee; Burton B Yang; Chun Peng
Journal:  Mol Biol Cell       Date:  2008-09-10       Impact factor: 4.138

10.  Skp2 deficiency inhibits chemical skin tumorigenesis independent of p27(Kip1) accumulation.

Authors:  Christopher Sistrunk; Sun Hye Kim; Xian Wang; Sung Hyun Lee; Yongbaek Kim; Everardo Macias; Marcelo L Rodriguez-Puebla
Journal:  Am J Pathol       Date:  2013-03-06       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.